Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression

Terfenadine resensitizes doxorubicin activity in drug-resistant ovarian cancer cells via an inhibition of CaMKII/CREB1 mediated ABCB1 expression

Ovarian cancer is one of the most lethal gynecological malignancies. Recurrence or acquired chemoresistance is the leading cause of ovarian cancer therapy failure. Overexpression of ATP-binding cassette subfamily B member 1 (ABCB1), commonly known as P-glycoprotein, correlates closely with multidrug...

Full description

Bibliographic Details
Main Authors: Wei Huang, Shu Yang, Yu-Shan Cheng, Ni Sima, Wei Sun, Min Shen, John C. Braisted, Weiguo Lu, Wei Zheng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Oncology
Subjects:
drug-resistant
ovarian cancer
terfenadine
CaMKII
doxorubicin
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1068443/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1068443/full

Similar Items